Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 7.3% – Still a Buy?

Posted by Brian Himes on Oct 15th, 2026

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) was up 7.3% during mid-day trading on Thursday. The company traded as high as $28.05 and last traded at $28.3340. Approximately 207,302 shares traded hands during trading, a decline of 88% from the average session volume of 1,781,984 shares. The stock had previously closed at $26.41.

Analysts Set New Price Targets

Several brokerages recently commented on ARQT. Morgan Stanley increased their price objective on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings downgraded Arcutis Biotherapeutics from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday. Needham & Company LLC raised their price objective on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen downgraded Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Finally, Cantor Fitzgerald assumed coverage on Arcutis Biotherapeutics in a research report on Thursday. They set an “overweight” rating and a $48.00 price objective for the company. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.33.

Check Out Our Latest Report on ARQT

Arcutis Biotherapeutics Trading Up 9.4%

The stock has a market cap of $3.63 billion, a PE ratio of 136.94 and a beta of 1.57. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.67 and a current ratio of 2.92. The stock has a fifty day moving average price of $25.32 and a 200 day moving average price of $24.73.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05. The firm had revenue of $129.86 million for the quarter, compared to the consensus estimate of $118.85 million. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%. Equities analysts expect that Arcutis Biotherapeutics, Inc. will post 0.42 EPS for the current year.

Insider Buying and Selling at Arcutis Biotherapeutics

In other news, Director Terrie Curran sold 38,200 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $25.03, for a total value of $956,146.00. Following the sale, the director owned 23,526 shares of the company’s stock, valued at approximately $588,855.78. This represents a 61.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Masaru Matsuda sold 9,989 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $25.03, for a total transaction of $250,024.67. Following the completion of the sale, the insider owned 116,182 shares of the company’s stock, valued at $2,908,035.46. This trade represents a 7.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 79,225 shares of company stock valued at $2,015,966. Insiders own 9.40% of the company’s stock.

Institutional Trading of Arcutis Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in ARQT. Arizona State Retirement System grew its stake in shares of Arcutis Biotherapeutics by 1.7% during the second quarter. Arizona State Retirement System now owns 30,802 shares of the company’s stock valued at $808,000 after buying an additional 521 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Arcutis Biotherapeutics by 0.4% during the first quarter. Bank of New York Mellon Corp now owns 305,532 shares of the company’s stock worth $7,198,000 after purchasing an additional 1,104 shares during the last quarter. KBC Group NV lifted its position in shares of Arcutis Biotherapeutics by 43.2% during the first quarter. KBC Group NV now owns 4,376 shares of the company’s stock worth $103,000 after purchasing an additional 1,321 shares during the last quarter. AMI Asset Management Corp lifted its position in shares of Arcutis Biotherapeutics by 3.2% during the first quarter. AMI Asset Management Corp now owns 50,863 shares of the company’s stock worth $1,198,000 after purchasing an additional 1,601 shares during the last quarter. Finally, Fishman Jay A Ltd. MI boosted its stake in shares of Arcutis Biotherapeutics by 0.4% during the first quarter. Fishman Jay A Ltd. MI now owns 566,730 shares of the company’s stock valued at $13,352,000 after purchasing an additional 2,080 shares during the period.

Arcutis Biotherapeutics Company Profile

(Get Free Report)

Arcutis Biotherapeutics, Inc (NASDAQ: ARQT) is a biopharmaceutical company focused on developing and commercializing treatments for dermatologic conditions. The company concentrates on medical dermatology, with an emphasis on addressing diseases that can significantly affect patients’ quality of life and for which additional treatment options are needed.

Arcutis’s primary commercial product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor available in multiple formulations.